menu
    • menu
    [{"orgOrder":0,"company":"Bial","sponsor":"Recipharm AB","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Opicapone","moa":"COMT","graph1":"Neurology","graph2":"Approved","graph3":"Bial","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bial \/ BIAL","highestDevelopmentStatusID":"12","companyTruncated":"Bial \/ BIAL"},{"orgOrder":0,"company":"Bial","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Termination","leadProduct":"Eslicarbazepine Acetate","moa":"Sodium channel alpha subunits","graph1":"Neurology","graph2":"Approved","graph3":"Bial","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bial \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Bial \/ Eisai"},{"orgOrder":0,"company":"Bial","sponsor":"Sunovion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Approved","graph3":"Bial","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Bial \/ BIAL","highestDevelopmentStatusID":"12","companyTruncated":"Bial \/ BIAL"},{"orgOrder":0,"company":"Bial","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"BIA 28-6156","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Bial","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Bial \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bial \/ Not Applicable"},{"orgOrder":0,"company":"Bial","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Opicapone","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Bial","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bial \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Bial \/ Amneal Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Bial

    Menu

    Bial

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bial

                            Portugal arrow
                            2024 ACI Convention
                            Not Confirmed

                            Bial

                            Portugal arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Opicapone

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Amneal Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)

                            Details : Under the agreement, Amneal will have exclusive rights to market and distribute ONGENTYS (opicapone), a highly-selective COMT inhibitor, which is approved by USFDA as an add-on treatment to carbidopa/levodopa in patients with Parkinson’s disease experi...

                            Brand Name : Ongentys

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 07, 2023

                            Lead Product(s) : Opicapone

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Amneal Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bial

                            Portugal arrow
                            2024 ACI Convention
                            Not Confirmed

                            Bial

                            Portugal arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BIA 28-6156

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BIAL R&D Announces First Patient Dosed in its Phase 2 Clinical Trial of BIA 28-6156 to Treat Parkinson's Disea...

                            Details : BIA 28-6156 is an allosteric activator of the enzyme beta-glucocerebrosidase (GCase) for the treatment of patients with Parkinson's disease (PD) who have a mutation in the glucocerebrosidase 1 (GBA1) gene (GBA-PD).

                            Brand Name : BIA 28-6156

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 25, 2023

                            Lead Product(s) : BIA 28-6156

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Bial

                            Portugal arrow
                            2024 ACI Convention
                            Not Confirmed

                            Bial

                            Portugal arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apomorphine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : Sunovion Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Sunovion and BIAL Enter European Licensing Agreement for Apomorphine Sublingual Film for the Treatment of Park...

                            Details : Under the terms of the agreement, BIAL will be responsible for regulatory approvals and submissions, including interactions with the European Medicines Agency (EMA) for APL-130277, which is currently in Phase 3 clinical development in Europe.

                            Brand Name : Kynmobi

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 02, 2021

                            Lead Product(s) : Apomorphine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : Sunovion Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Bial

                            Portugal arrow
                            2024 ACI Convention
                            Not Confirmed

                            Bial

                            Portugal arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eslicarbazepine Acetate

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Eisai

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            BIAL Takes the Lead in Europe for the Commercialisation of Epilepsy Treatment, Zebinix® Expanding Neurology F...

                            Details : BIAL takes the lead for the marketing and distribution of Zebinix® (eslicarbazepine acetate) in Europe. Eslicarbazepine acetate is a once-daily anti-epileptic used to treat epilepsy patients with focal seizures (partial-onset seizures).

                            Brand Name : Zebinix

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 17, 2021

                            Lead Product(s) : Eslicarbazepine Acetate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Eisai

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Bial

                            Portugal arrow
                            2024 ACI Convention
                            Not Confirmed

                            Bial

                            Portugal arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Opicapone

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : Recipharm AB

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            BIAL and Recipharm Expand Long-Term Supply Agreement for Opicapone API

                            Details : The new agreement provides both companies with a long-term partnership that will ensure continued supply for patients across the globe. Opicapone (Ongentys) is approved in Europe, USA, South Korea, Taiwan, Australia and Japan.

                            Brand Name : Ongentys

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 01, 2020

                            Lead Product(s) : Opicapone

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : Recipharm AB

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth